GSK:LON
GSK plc
၁,၇၄၀.၀၀ GBX
arrow_downward
-၀.၇၄%(-၁၃.၀၀) 1D
အောက် ၁၄, GMT+၁ ၁၇:၀၀:၀၄ · GBX
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for GSK...
Open
၁,၇၄၀.၀၀ GBX
High
၁,၈၁၆.၀၀ GBX
Low
၁,၇၄၀.၀၀ GBX
Mkt. cap
ဋေ ၉.၇၀ ထ
Avg. vol.
၆.၀၇ သန်း
Volume
၇.၄၃ သန်း
Dividend
၃.၉၁%
Quarterly dividend
၁၇.၀၀ GBX
Ex-dividend date
၂၀၂၆ ဩ ၁၃
P/E ratio
၁၄.၇၅
52-wk high
၂,၂၈၂.၀၀ GBX
52-wk low
၁,၅၉၂.၀၀ GBX
EPS
၁.၁၈ GBX
Shares outstanding
၄၃၁.၆၃ ဋေ
No. of employees
၇ သောင်း
Open
၁,၇၄၀.၀၀ GBX
High
၁,၈၁၆.၀၀ GBX
Low
၁,၇၄၀.၀၀ GBX
Mkt. cap
ဋေ ၉.၇၀ ထ
Avg. vol.
၆.၀၇ သန်း
Volume
၇.၄၃ သန်း
Dividend
၃.၉၁%
Quarterly dividend
၁၇.၀၀ GBX
Ex-dividend date
၂၀၂၆ ဩ ၁၃
P/E ratio
၁၄.၇၅
52-wk high
၂,၂၈၂.၀၀ GBX
52-wk low
၁,၅၉၂.၀၀ GBX
EPS
၁.၁၈ GBX
Shares outstanding
၄၃၁.၆၃ ဋေ
No. of employees
၇ သောင်း
News stories
From web sources and news partners
Stock Titan
·
ပြီးခဲ့သည့် ၅၂ မိနစ်
At £17.3550 per ordinary share, dividend reinvestment adds to GSK (GSK) executives’ interests.
TipRanks
·
ပြီးခဲ့သည့် ၁ နာရီ
GSK executives report dividend-driven increases in deferred share interests
Reuters
·
ပြီးခဲ့သည့် ၁ နာရီ
GSK plans to cut up to 1,217 jobs in Belgium as it begins three-year restructuring plan
marketscreener.com
·
ပြီးခဲ့သည့် ၂ နာရီ
Berenberg still a buyer of GSK, considering stock undervalued
Profile
GSK plc is a British multinational pharmaceutical and biotechnology company. It was established in 2000 by a merger of Glaxo Wellcome and SmithKline Beecham, which was itself a merger of a number of pharmaceutical companies around the Smith, Kline & French firm. It is headquartered in London, England.
GSK is the tenth-largest pharmaceutical company in the world by earnings, $9.32 billion in 2025 with $42.4 billion in revenues in the same period. As of February 2026 it is the 175th most valuable company in the world and the 12th most valuable pharmaceutical company with a market capitalisation of $122.6 billion. It was also ranked 388th on the 2025 Fortune Global 500.
The company has a primary listing on the London Stock Exchange and is a constituent of the FTSE 100 Index, the eighth largest on the London Stock Exchange behind British pharmaceutical rival AstraZeneca, which occupies the No 1 spot in London at a value of $325 billion, 2.7x more than GSK.
The company developed the first malaria vaccine, RTS, S, which it said in 2014, it would make available for five per cent above cost. Wikipedia
About GSK plc
CEOEmma Walmsley | Emma Walmsley
Employees၆.၆၈ သောင်း
Founded၂၀၀၀ ဒီ ၂၇
Headquarters-
Sector-
Websitegsk.com